INSCRIPTA ACHIEVES IMPORTANT MILESTONE AND DEMONSTRATES ITS NOVEL WHOLE GENOME ENGINEERING BIOTECHNOLOGY PLATFORM WITH ACCELERATED TIMELINES PLEASANTON, Calif. , Nov. 7, 2024 /PRNewswire/ -- Inscripta, Inc.
, a leading life science technology company helping to create the bioeconomy, has successfully completed scale-up runs and is moving into commercial manufacturing of an anti-aging skincare ingredient. Commercial biomanufacturing addresses serious challenges in sourcing plant-based ingredients. These challenges include the environmental footprint associated with current extractive sourcing and the limited depth and consistency of supply chains, which can negatively impact availability and affordability.
In addition, biomanufacturing eliminates sensitizing impurities native to plant-based extracts. Inscripta is engaged with commercial partners to deliver an ingredient product with demonstrated efficacy, superior quality, and consistency that will benefit branded manufacturers and their customers. "There is an incredible opportunity for the bioeconomy to meet global consumer demands, not just in personal care, but well beyond by improving sustainability, stabilizing supply chains, and reducing time to market," said Sri Kosaraju , Inscripta President & CEO.
"We not only develop robust and productive strains, but we also create scalable manufacturing supply chains that deliver sought-after materials to market." Inscripta's development program leveraged its GenoScaler TM technolo.